Screener
Sionna Therapeutics SION Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | 1,209 | 3,554 |
| Accrued expenses and other current liabilities | (3,463) | (4,320) |
| Operating lease liabilities | (543) | (528) |
| Net cash used in operating activities | (21,840) | (16,288) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (86) |
| Purchases of marketable securities | (25,327) | (171,595) |
| Maturities of marketable securities | 50,147 | 30,487 |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's operating cash flow?
- Sionna Therapeutics (SION) reported operating cash flow of -$21.84M in Q1 2026.
- How has Sionna Therapeutics's operating cash flow changed year-over-year?
- Sionna Therapeutics's operating cash flow decreased by 34.1% year-over-year, from -$16.29M to -$21.84M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Sionna Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude